Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis

P Rich, RK Scher - Journal of the American Academy of Dermatology, 2003 - Elsevier
The Nail Psoriasis Severity Index (NAPSI) is a numeric, reproducible, objective, simple tool
for evaluation of nail psoriasis. This scale is used to evaluate the severity of nail bed …

Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group …

…, M Iorizzo, M Pasch, BM Piraccini, P Rich… - Journal of the American …, 2019 - Elsevier
Nail involvement in psoriasis is common, and the severity of it does not always parallel the
intensity of cutaneous disease. We created a consensus group, of which the aim was to …

The epidemiology, etiology, and pathophysiology of onychomycosis

RK Scher, P Rich, D Pariser, B Elewski - , 32, 2013 - ingentaconnect.com
The prevalence of onychomycosis in the United States is estimated to be at least 12%;
prevalence increases with increasing age and is highest in individuals more than 65 years of age. …

Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding …

P Rich, B Sigurgeirsson, D Thaci… - British Journal of …, 2013 - academic.oup.com
Background Interleukin (IL)‐17A has major proinflammatory activity in psoriatic lesional skin.
Objectives To assess the efficacy and safety of secukinumab, a fully human IgG1κ …

[HTML][HTML] Melanonychia

J Jefferson, P Rich - Dermatology Research and Practice, 2012 - hindawi.com
Melanonychia, or melanin-derived brown-to-black nail pigmentation, is a diagnostic challenge
for clinicians. The most serious disease of the nail unit, melanoma, primarily presents with …

[HTML][HTML] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double …

…, H Sofen, L Kircik, KB Gordon, P Foley, P Rich… - Journal of the American …, 2023 - Elsevier
… Dr Rich has received research grants as a principal investigator on pharmaceutical trials
from AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Sun Pharma…

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

JK Geisse, P Rich, A Pandya, K Gross, K Andres… - Journal of the American …, 2002 - Elsevier
Background: Imiquimod 5% cream may provide an effective nonsurgical treatment for
superficial basal cell carcinoma (sBCC) based on results of previous studies. Objective: The …

Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies

BE Elewski, P Rich, R Pollak, DM Pariser… - Journal of the American …, 2013 - Elsevier
BACKGROUND: Onychomycosis is a common nail infection, often resulting in nail plate
damage and deformity. Topical lacquer treatments have negligible efficacy. Oral treatments, …

Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of …

…, GF Webster, M Jackson, M Rendon, P Rich… - Journal of the American …, 2007 - Elsevier
BACKGROUND: Doxycycline monotherapy at antimicrobial doses has been shown to be
effective for the treatment of rosacea. OBJECTIVE: To evaluate the efficacy and safety of once-…

[PDF][PDF] Efficacy and safety of a new triple-combination agent for the treatment of facial melasma

SC Taylor, H Torok, T Jones, N Lowe, P Rich… - CUTIS-NEW …, 2003 - cdn.mdedge.com
Methods Study Design—The 2 pivotal trials used similar multicenter, randomized, investigator-blind,
activecontrol, parallel-group protocols. Thirteen centers were involved in these trials…